vyndaqel
pfizer europe ma eeig - tafamidis - amiloidoze - other nervous system drugs - vyndaqel tiek norādīts transthyretin amyloidosis pieaugušiem pacientiem ar 1. posms simptomātiska polineiropātijas aizkavēt perifērijas neiroloģisku traucējumu ārstēšanai.
zinforo
pfizer ireland pharmaceuticals - ceftarolīna fosamils - community-acquired infections; skin diseases, infectious; pneumonia - antibakteriālas līdzekļi sistēmiskai lietošanai, - zinforo is indicated for the treatment of the following infections in neonates, infants, children, adolescents and adults: , complicated skin and soft tissue infections (cssti), community-acquired pneumonia (cap) , consideration should be given to official guidance on the appropriate use of antibacterial agents.
ucedane
eurocept international bv - carglumic acid - hyperammonemia; amino acid metabolism, inborn errors - citas gremošanas trakta un metabolisma produkti, - ucedane is indicated in treatment of:hyperammonaemia due to n-acetylglutamate synthase primary deficiency;hyperammonaemia due to isovaleric acidaemia;hyperammonaemia due to methymalonic acidaemia;hyperammonaemia due to propionic acidaemia.
tremfya
janssen-cilag international nv - guselkumabs - psoriāze - imūnsupresanti - plaque psoriasis tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritis tremfya, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (dmard) therapy (see section 5.
xermelo
serb sas - telotristāts etirāts - carcinoid tumor; neuroendocrine tumors - citi gremošanas trakta un vielmaiņas produkti - xermelo ir indicēts kancerogēna sindroma caurejas ārstēšanai kombinācijā ar somatostatīna analogu (ssa) terapiju pieaugušajiem, kuriem nepietiekami kontrolēts ssa terapija.
kriptazen
virbac s.a. - halofuginons - antiprostozie līdzekļi - teļi, jaundzimušie - in new born calves:- prevention of diarrhoea due to diagnosed cryptosporidium parvum, in farms with history of cryptosporidiosis,administration should start in the first 24 to 48 hours of age- reduction of diarrhoea due to diagnosed cryptosporidium parvum. lietošana jāuzsāk 24 stundu laikā pēc caurejas iestāšanās. abos gadījumos ir pierādīta oocista izdalīšanās samazināšanās.
namuscla
lupin europe gmbh - meksiletīna hidrohlorīds - myotonic traucējumiem - sirds terapija - namuscla ir norādīts simptomātiska ārstēšana myotonia pieaugušo pacientiem ar ne-eitro myotonic traucējumiem.
xenleta
nabriva therapeutics ireland dac - lefamulin acetate - pneumonia, bacterial; community-acquired infections - antibakteriālas līdzekļi sistēmiskai lietošanai, - xenleta is indicated for the treatment of community-acquired pneumonia (cap) in adults when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of cap or when these have failed. jāņem vērā oficiālās vadlīnijas par piemērotu izmantot antibakteriālas vielas.
livogiva
theramex ireland limited - teriparatide - osteoporoze - kalcija homeostāze - livogiva is indicated in adults. osteoporozes ārstēšana sievietēm pēc menopauzes un vīriešiem ar paaugstinātu lūzuma risku. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. attieksmi pret osteoporozi saistīts ar ilgstošu sistēmisku glikokortikoīdu terapiju sievietēm, gan vīriešiem, paaugstināts lūzums.
enteroporc coli
ceva santé animale - inactivated fimbrial adhesins of escherichia coli f4ab, inactivated fimbrial adhesins of escherichia coli f4ac, inactivated fimbrial adhesins of escherichia coli f5, inactivated fimbrial adhesins of escherichia coli f6 - imunoloģiskie līdzekļi suidae - cūkas - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6.